NAMS (NewAmsterdam Pharma Co NV) Future 3-5Y EPS without NRI Growth Rate : 6.32 (As of Dec. 15, 2024)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, NewAmsterdam Pharma Co NV's Future 3-5Y EPS without NRI Growth Rate is 6.32.

Competitive Comparison of NewAmsterdam Pharma Co NV's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Future 3-5Y EPS without NRI Growth Rate falls into.

NewAmsterdam Pharma Co NV (NAS:NAMS) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

NewAmsterdam Pharma Co NV Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.